Low-dose antithymocyte globulin (ATG) works in clinical trials for type 1 diabetes. Can it work in a real clinic? A recent study co-authored by GCDTR’s Brittany S. Bruggeman, Laura M. Jacobsen, and Desmond A. Schatz, published in Diabetes Care, examined low-dose ATG monitoring using a modified quantitative response (mQR) of C-peptide in a clinical practice setting.
Key findings: Of 22 evaluable patients, 15 (68%) were responders with a positive mQR after one year of follow-up Average HbA1c decreased from 7.1% (54 mmol/mol) to 6.0% (42 mmol/mol) at one year C-peptide mQR monitoring was feasible in a real-world setting with no unexpected side effects lnkd.in/eYPAfu74
